RVL Pharmaceuticals plc

+0.03 (+2.33%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)106.87M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.67 Million
Adjusted EPS-$0.24
See more estimates
10-Day MA$1.29
50-Day MA$1.42
200-Day MA$1.62
See more pivots

RVL Pharmaceuticals plc Stock, NASDAQ:RVLP

400 Crossing Boulevard, Bridgewater, New Jersey 08807
United States of America
Phone: +1.908.809.1300
Number of Employees: 156


RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.